Adjuvant setting: 1 trials - BRIM 8
| vemurafenib vs placebo | No demonstrated result suggested progression or death (progression free survival PFS) by 35% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | distant metastasis free survival | no data | | recurrence free survival | no data | | death (overall survival) | 0.72 [0.45 1.16] | p=1.00 | 0 | 498 | 1 | BRIM 8, | | progression or death (progression free survival PFS) | 0.65 [0.50 0.85] | p=0.04 | 0 | -18 | 1 | BRIM 8, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Adjuvant stage III only - NOVARTIS : 1 trials - BRIM 8 (cohort IIIC)
| vemurafenib vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | distant metastasis free survival | 0.91 [0.57 1.45] | p=1.00 | 0 | -18 | 1 | BRIM 8 (cohort IIIC), | | recurrence free survival | 0.80 [0.54 1.18] | p=1.00 | 0 | -18 | 1 | BRIM 8 (cohort IIIC), | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.80 [0.54 1.18] | p=1.00 | 0 | -18 | 1 | BRIM 8 (cohort IIIC), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - BRIM 8
| vemurafenib vs placebo | No demonstrated result suggested progression or death (progression free survival PFS) by 35% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | distant metastasis free survival | no data | | recurrence free survival | no data | | death (overall survival) | 0.72 [0.45 1.16] | p=1.00 | 0 | 498 | 1 | BRIM 8, | | progression or death (progression free survival PFS) | 0.65 [0.50 0.85] | p=0.04 | 0 | -18 | 1 | BRIM 8, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
